chr3-129062205-G-A
Variant summary
Our verdict is Benign. The variant received -8 ACMG points: 1P and 9B. PS3_SupportingBA1BP4
This summary comes from the ClinGen Evidence Repository: The c.466G>A (p.Ala156Thr) variant in GP9 is a missense variant predicted to cause substitution of alanine by threonine at amino acid 156. At least one patient (Case in PMID:15351858 or internal) with this variant had aggregation absent for ristocetin and present for all other agonists, which is highly specific for Bernard-Soulier syndrome. Additionally, the patient had excessive mucocutaneous bleeding and macrothrombocytopenia which is consistent with Bernard-Soulier syndrome, however this variant has a Grpmax Filtering allele frequency in gnomAD v4.1 is 0.2194 (based on 9530/42710 alleles) in the East Asian population, which is higher than the ClinGen PD VCEP threshold (>0.001), and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.187, which is below the ClinGen PD VCEP threshold of <0.290 and predicts no damaging effect on GP9 function and splicing predictor SpliceAI predicts no impact on splicing with delta scores of 0.00 (BP4). Surface expression of GPIBa and GP9 measured by flow cytometry in CHO cells in cells transiently co-transfected with the c.466G>A variant and wild type GP1a and GP1b showed decreased expression at very low (<25%) WT levels, indicating that this variant impacts protein function (PMID:15351858)(PS3_supporting). In summary with BP4 (-1), BA1, PS3_supporting (+1), the other criteria cancel out and BA1 alone provides a Benign classification, ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP. LINK:https://erepo.genome.network/evrepo/ui/classification/CA202222/MONDO:0009276/083
Frequency
Consequence
NM_000174.5 missense
Scores
Clinical Significance
Conservation
Publications
- Bernard-Soulier syndromeInheritance: AR, AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -8 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0164 AC: 2492AN: 152196Hom.: 168 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0471 AC: 7662AN: 162702 AF XY: 0.0411 show subpopulations
GnomAD4 exome AF: 0.0125 AC: 17669AN: 1414042Hom.: 1339 Cov.: 32 AF XY: 0.0125 AC XY: 8786AN XY: 700190 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0163 AC: 2486AN: 152314Hom.: 168 Cov.: 33 AF XY: 0.0183 AC XY: 1364AN XY: 74476 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Benign:3
- -
- -
This variant is associated with the following publications: (PMID: 20981092, 11758225, 27884173, 27291889) -
Bernard Soulier syndrome Benign:3
This variant is interpreted as a Benign - Stand Alone, for Bernard Soulier syndrome, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: BP4 => Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.). BA1 => Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. BS2 => Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age. -
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
The c.466G>A (p.Ala156Thr) variant in GP9 is a missense variant predicted to cause substitution of alanine by threonine at amino acid 156. At least one patient (Case in PMID:15351858 or internal) with this variant had aggregation absent for ristocetin and present for all other agonists, which is highly specific for Bernard-Soulier syndrome. Additionally, the patient had excessive mucocutaneous bleeding and macrothrombocytopenia which is consistent with Bernard-Soulier syndrome, however this variant has a Grpmax Filtering allele frequency in gnomAD v4.1 is 0.2194 (based on 9530/42710 alleles) in the East Asian population, which is higher than the ClinGen PD VCEP threshold (>0.001), and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.187, which is below the ClinGen PD VCEP threshold of <0.290 and predicts no damaging effect on GP9 function and splicing predictor SpliceAI predicts no impact on splicing with delta scores of 0.00 (BP4). Surface expression of GPIBa and GP9 measured by flow cytometry in CHO cells in cells transiently co-transfected with the c.466G>A variant and wild type GP1a and GP1b showed decreased expression at very low (<25%) WT levels, indicating that this variant impacts protein function (PMID:15351858)(PS3_supporting). In summary with BP4 (-1), BA1, PS3_supporting (+1), the other criteria cancel out and BA1 alone provides a Benign classification, ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP. -
not specified Benign:2
- -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at